Phuturdex › Diseases › Dermatitis
Drugs in development · updated 30 October 2026
Dermatitis: drugs in development
As of 30 October 2026 there are 23 active clinical trials (recruiting or ongoing, phases I–III) on 29 drugs for dermatitis. 12 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| TilrekimigPF-07275315 | III | 2 | NCT07783425 |
| PG-011Gel | III | 1 | NCT06587685 |
| Squaric Acid Dibutyl Ester | II–III | 1 | NCT05535738 |
| IMG-007 | II | 2 | NCT07037901 |
| ATI-045 | II | 1 | NCT07011706 |
| BempikibartADX-914 | II | 1 | NCT06018428 |
| Camoteskimab | II | 1 | NCT07599813 |
| GHZ339 | II | 1 | NCT06947993 |
| Tibulizumab | II | 1 | NCT06993610 |
| Zabalafin | II | 1 | NCT06855745 |
| REGN20423 | I | 1 | NCT07527923 |
| SHR-1894 | I | 1 | NCT07414602 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DupilumabDUPIXENT | II–III | 3 | NCT05535738 |
| LebrikizumabEbglyss® | III | 3 | NCT07542483 |
| RemibrutinibLOU064, Rhapsido® | III | 2 | NCT06840392 |
| AbrocitinibCibinqo® | III | 1 | NCT06807268 |
| AdalimumabHadlima, Simlandi® | II–III | 1 | NCT05535738 |
| Betamethasone ValerateLuxiq®, Betatrex® | II–III | 1 | NCT05535738 |
| CanakinumabIlaris®, Canakinumab Novartis® | II–III | 1 | NCT05535738 |
| Fluticasone PropionateFluticasone, Xhance® | II–III | 1 | NCT05535738 |
| GuselkumabTremfya | II–III | 1 | NCT05535738 |
| SarilumabSAR153191 SC, Kevzara | II–III | 1 | NCT05535738 |
| Triamcinolone Acetonidezilretta, Kenalog { | II–III | 1 | NCT05535738 |
| UstekinumabPyzchiva®, Starjemza® | II–III | 1 | NCT05535738 |
| CephalexinKeftab®, Keflet® | II | 1 | NCT01631617 |
| DoxycyclineDoxycyclin, Lymepak® | II | 1 | NCT01631617 |
| SulfamethoxazoleGantanol®, Gantanol-Ds® | II | 1 | NCT01631617 |
Sorted by most advanced phase and number of active trials. Showing 15 of 17 drugs.
All 29 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Atopic dermatitis 91 drugs
- Eczema 27 drugs
- Pruritus 18 drugs
- Drug Hypersensitivity Syndrome 4 drugs
- Dermatitis, Seborrheic 3 drugs
- Hidradenitis suppurativa 36 drugs
- Rheumatoid arthritis 130 drugs
- Psoriasis 46 drugs
- Liver Cirrhosis, Biliary 13 drugs
- Sclerosing cholangitis 17 drugs
- Ascending cholangitis 3 drugs
- Digestive System Diseases 36 drugs
Broader categories
- Skin and connective tissue diseases 3 drugs
- Hypersensitivity 22 drugs
- Genetic disease 33 drugs
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Skin disease 34 drugs
- Eczematous skin disease 3 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D003872 “Dermatitis”.